Updated Overall Survival Data From Pivotal Herceptin Adjuvant,Studies in HER2-Positive Breast Cancer ( ...)

(Date:5/15/2008)... France, May 15 /- Cerenis,Therapeuti...ompany,developing HDL-related compounds for the tr...today announced that it has completed a Phase I,cl...d product candidates.,CER-002 is a peroxisome prol...agonist in development for the treatment of cardio...

(Date:5/15/2008)... CenterWatch, a publishing and,information service...l,trials, finds that investigative sites are requi...) systems. More than 75% of respondents to a recen...trained on three or more,EDC systems. In addition,...eir EDC training had improved., State of the Clin...

(Date:5/15/2008)...wire-FirstCall/ -- Novavax, Inc. (Nasdaq:,NVAX) to...the Phase I/IIa,study of its pandemic influenza va...cts. Favorable interim results from the first phas...70 healthy adult volunteers, were,reported in Dece... vaccine,is well tolerated and immunogenic at the ...

(Date:5/15/2008)... Plan Positions Blue Cross Blue Shield of Mic...rt from HealthLeaders-Inter...ealthLeaders-InterStudy, the,leading provider of m...he,economy continues to stagnate in Michigan, Blue...uipped of all of its competitors to weather the,ec...

Breaking Medicine Technology:Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease 2 CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence 2 Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial 2 Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial 3 Blue Cross Blue Shield Of Michigan Battles Sluggish Economy With Diverse Product Lineup 2 Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 1 Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 2 Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 3 Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 4 Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 5 Phlo Reports Sharp Revenue Increase 3441 1 Phlo Reports Sharp Revenue Increase 3441 2 Cancer Cure Coalition Proposes Major Changes at the FDA 1404 1 Cancer Cure Coalition Proposes Major Changes at the FDA 1404 2 Cancer Cure Coalition Proposes Major Changes at the FDA 1404 3 Lack of political will and the subordination of women are major barriers to tackling AIDS 12406 1 Lack of political will and the subordination of women are major barriers to tackling AIDS 12406 2 Lack of political will and the subordination of women are major barriers to tackling AIDS 12406 3 Lack of political will and the subordination of women are major barriers to tackling AIDS 12406 4

[0] Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease [0] CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence [0] Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial [0] Blue Cross Blue Shield Of Michigan Battles Sluggish Economy With Diverse Product Lineup

...r 17, 2007 - ZIOPHARM Oncology,Inc. (NASDAQ: ZIOP...data strongly supportive of the development of an ...trates very high,bioavailability when administered...activity that is particularly well suited to oral,...eparate posters,today at the American Association ...

...r 17, 2007 - Cougar Biotechnology,Inc. (OTCBB:CGR...,II data on the Company,s prostate cancer drug can...at the American Association for,Cancer Research (A...e data was presented in two oral presentations as ...pt Late-Breaking Clinical,Trials. These presentati...

Other Medicine Technology:ZIOPHARM Presents Data Highlighting Oral ZIO-101 at AACR 2 ZIOPHARM Presents Data Highlighting Oral ZIO-101 at AACR 3 Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR,Annual Meeting Late-Breaking Clinical Trials Session 2 Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR,Annual Meeting Late-Breaking Clinical Trials Session 3 Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR,Annual Meeting Late-Breaking Clinical Trials Session 4 Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR,Annual Meeting Late-Breaking Clinical Trials Session 5

ZIOPHARM Presents Data Highlighting Oral ZIO-101 at AACR Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR,Annual Meeting Late-Breaking Clinical Trials Session

(Date:5/16/2008)... HAE: TSX, MONTREAL...ation,(TSX:HAE), a specialty bio-therapeutics comp...rcialization, announced today that its Chairman of...li, will present at the,upcoming Rodman & Renshaw ..., May 20, 2008 in the Zephyr Room at Le Meridien B...

(Date:5/16/2008)... SAO PAULO, Brazil, May 16 /PRNewswire-FirstCall/ ...rs: TEMP3.SA; Bloomberg: TEMP3 BZ), a leading,prov... benefit plans and,specialized assistance services...r of 2008. The operating and financial information...d, is presented in Brazilian Reais and in,accordan...

(Date:5/15/2008)...PHILADELPHIA) Combining natural organic atoms wit...ute have developed a new type of enzyme inhibitor ...ys a key role in cancer development. , Based on...es the way for developing new ways to treat cancer...leads to uncontrolled tumor growth. , Details of...

(Date:5/15/2008)... HARBIN, China, May 15 /Xinhua-PRNewswire-FirstCal...tin Board: CYXI) ("China Yingxia" or "the,Company"...y engaged in the,development, manufacture and dist...plements, and personal care products in the People...inancial results for the first,quarter ended March...

[0] Haemacure announces webcast of presentation at Rodman & Renshaw 5th Annual Global Healthcare Conference [0] Tempo Participacoes Announces Increase of 34% in EBITDA and of 25% in Net Revenue for the 1Q08 [0] Novel enzyme inhibitor paves way for new cancer drug [0] China Yingxia International, Inc. Reports First Quarter 2008 Results

...Daniel Stetson have reported in the Journal Immuni...rent mechanism to viral DNA infection. // Viruses...to DNA and RNA viruses and researchers have found ...ognisation of these viral products in the host is ...

...ngcheng Zhang from Whitehead Institute for Biomedi... of growth factors// which enriches and increases ...it could be injected into the recipient. Stem ce... stem cells required for a therapy is very high an...

...om Motor Neurone Disease (MND), a fatal nerve dise...a simple ventilator and facemask//. Patients suff...it from the new technique called non-invasive vent...e with MND who suffer from weakness of the respira...

...ffective as it is claimed to be. Therefore purchas...t// is viewed as nothing more than a waste of mone... on the above finding, several recommendations hav...treatment of coughs by the American College of Che...

Other Medicine News:

Specific Immune Mechanism against DNA viruses Combination growth factors for Stem cell proliferation Respirator Can Improve Quality Of Life Of Motor Neurone Disease Patients Cough Syrups No More Effective Than Sugar Water

... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...

Medicine Products:

Antibiotic MIC/MBC Antibiotic Level, Piperacillin Antibiotic Level, Ciprofloxacin Anti-TPO

( ...)Updated Overall Survival Data From Pivotal Herceptin Adjuvant,Studies in HER2-Positive Breast Cancer,Health